LIMK1 Inhibitors - A Novel, Disease-Modifying Approach for the Treatment of Fragile X Syndrome (Developmental Pathways Funding Scheme - Full Stage) (Joint with Cardiff University and University of Oxford)

Lambert, Jeremy (Investigator)

Neuroscience

Status	Finished
Effective start/end date	1/05/19 → 31/12/21

UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This project contributes towards the following SDG(s):

SDG 3 Good Health and Well-being

Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome
Baldwin, A. G., Foley, D. W., Collins, R., Lee, H., Jones, D. H., Wahab, B., Waters, L., Pedder, J., Paine, M., Feng, G. J., Privitera, L., Ashall-Kelly, A., Thomas, C., Gillespie, J. A., Schino, L., Belelli, D., Rocha, C., Maussion, G., Krahn, A. I. & Durcan, T. M. & 4 others, Elkins, J. M., Lambert, J. J., Atack, J. R. & Ward, S. E. (Lead / Corresponding author), 9 Jan 2025, In: Journal of Medicinal Chemistry. 68, 1, p. 719-752 34 p.
Research output: Contribution to journal › Article › peer-review

Open Access
File
6 Link opens in a new tab Citations (Scopus)

97 Downloads (Pure)

LIMK1 Inhibitors - A Novel, Disease-Modifying Approach for the Treatment of Fragile X Syndrome (Developmental Pathways Funding Scheme - Full Stage) (Joint with Cardiff University and University of Oxford)

Project Details

UN Sustainable Development Goals

Fingerprint

Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome

LIMK1 Inhibitors - A Novel, Disease-Modifying Approach for the Treatment of Fragile X Syndrome (Developmental Pathways Funding Scheme - Full Stage) (Joint with Cardiff University and University of Oxford)

Project Details

UN Sustainable Development Goals

Fingerprint

Research output

Discovery of MDI-114215: A Potent and Selective LIMK Inhibitor To Treat Fragile X Syndrome